Study #2023-0274
A randomized, open-label, multicenter phase III study evaluating efficacy and safety of Mosunetuzumab in combination with Polatuzumab Vedotin in comparison with Rituximab in combination with Gemcitabine plus Oxaliplatin in participants with relapsed or refractory aggressive B-cell non-Hodgkin's Lymphoma.
MD Anderson Study Status
Not Accepting
Treatment Agent
Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin
Description
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Hodgkin Lymphoma
Study phase:
Phase III
Physician name:
Jason Westin
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-855-893-4229
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.